Search
Clozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigational[A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. … Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.
Atractylodes japonica root oil
go.drugbank.com/drugs/DB11270ApprovedWithdrawnAtractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia. … It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalIt inhibits virus replication by the same mechanism of action as BVM.
Propylthiouracil
go.drugbank.com/drugs/DB00550Approved(From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigational[A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression. … This approval was based on favorable results from 2 phase 3 clinical trials.[L47691]
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Pyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisSargramostim
go.drugbank.com/drugs/DB00020ApprovedInvestigationalSubstitution of Leu23 leads to a difference from native protein.
Gataparsen
go.drugbank.com/drugs/DB05141InvestigationalLY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. … LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung, colon, breast, prostate, ovary, cervix, skin and brain.